X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1207) 1207
male (654) 654
clopidogrel (597) 597
female (575) 575
ticlopidine - analogs & derivatives (531) 531
purinergic p2y receptor antagonists - therapeutic use (501) 501
purinergic p2y receptor antagonists - adverse effects (494) 494
middle aged (489) 489
aged (448) 448
platelet aggregation inhibitors - therapeutic use (443) 443
platelet aggregation inhibitors - adverse effects (440) 440
treatment outcome (430) 430
cardiac & cardiovascular systems (404) 404
adenosine - analogs & derivatives (396) 396
purinergic p2y receptor antagonists - administration & dosage (381) 381
percutaneous coronary intervention (370) 370
ticagrelor (345) 345
platelet aggregation inhibitors - administration & dosage (331) 331
prasugrel (313) 313
ticlopidine - therapeutic use (295) 295
acute coronary syndromes (275) 275
acute coronary syndrome - drug therapy (261) 261
aspirin (257) 257
blood platelets - drug effects (249) 249
risk factors (248) 248
hemorrhage - chemically induced (242) 242
prasugrel hydrochloride (224) 224
ticlopidine - adverse effects (221) 221
platelet aggregation - drug effects (220) 220
abridged index medicus (210) 210
animals (206) 206
time factors (203) 203
pharmacology & pharmacy (202) 202
adenosine - therapeutic use (200) 200
adenosine - adverse effects (192) 192
drug therapy, combination (187) 187
ticlopidine - administration & dosage (186) 186
blood platelets - metabolism (184) 184
antiplatelet therapy (182) 182
cardiovascular (182) 182
platelet function tests (177) 177
prospective studies (177) 177
acute coronary syndrome (175) 175
purinergic p2y receptor antagonists - pharmacology (173) 173
platelet aggregation inhibitors - pharmacology (166) 166
blood platelets (160) 160
heart attacks (157) 157
adenosine - administration & dosage (155) 155
cardiac patients (155) 155
percutaneous coronary intervention - adverse effects (155) 155
coronary heart disease (154) 154
aspirin - therapeutic use (153) 153
hematology (152) 152
peripheral vascular disease (149) 149
thrombosis (144) 144
adult (143) 143
receptors, purinergic p2y12 - drug effects (142) 142
myocardial-infarction (139) 139
inhibition (137) 137
care and treatment (134) 134
cardiology (130) 130
stents (129) 129
drug therapy (128) 128
thiophenes - therapeutic use (124) 124
piperazines - therapeutic use (123) 123
dose-response relationship, drug (117) 117
platelet inhibition (117) 117
purinergic p2y receptor antagonists - pharmacokinetics (113) 113
analysis (112) 112
receptors, purinergic p2y12 - blood (112) 112
outcomes (110) 110
adenosine (107) 107
intervention (107) 107
thiophenes - adverse effects (107) 107
cardiovascular disease (106) 106
mortality (106) 106
piperazines - adverse effects (106) 106
platelet aggregation inhibitors - pharmacokinetics (106) 106
purinergic p2 receptor antagonists (106) 106
acute coronary syndrome - therapy (105) 105
therapy (104) 104
risk assessment (103) 103
aspirin - administration & dosage (102) 102
myocardial infarction (102) 102
aggregation (101) 101
ticlopidine - pharmacology (101) 101
elevation myocardial-infarction (99) 99
myocardial infarction - drug therapy (97) 97
drug administration schedule (96) 96
aspirin - adverse effects (95) 95
platelets (95) 95
platelet activation - drug effects (94) 94
adenosine monophosphate - analogs & derivatives (93) 93
patients (93) 93
platelet reactivity (91) 91
aged, 80 and over (90) 90
follow-up studies (89) 89
bleeding (87) 87
p2y (87) 87
double-blind (85) 85
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1303) 1303
German (19) 19
French (6) 6
Italian (4) 4
Spanish (4) 4
Danish (3) 3
Russian (3) 3
Japanese (2) 2
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 2016, Volume 375, Issue 25, pp. 2423 - 2434
... – 3 Dual antiplatelet therapy (DAPT) with a P2Y 12 inhibitor and aspirin is superior to oral anticoagulation with a vitamin K antagonist in reducing the risk of thrombosis in patients undergoing placement of a first-generation stent, 4... 
MEDICINE, GENERAL & INTERNAL | PERCUTANEOUS CORONARY INTERVENTION | THERAPY | RIVAROXABAN | OPEN-LABEL | ANTITHROMBOTIC STRATEGIES | ANTICOAGULATION | Confidence Intervals | Humans | Middle Aged | Male | Hemorrhage - prevention & control | Rivaroxaban - administration & dosage | Factor Xa Inhibitors - administration & dosage | Purinergic P2Y Receptor Antagonists - adverse effects | Vitamin K - antagonists & inhibitors | Rivaroxaban - adverse effects | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Female | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Stents | Purinergic P2Y Receptor Antagonists - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Atrial Fibrillation - drug therapy | Atrial Fibrillation - therapy | Kaplan-Meier Estimate | Factor Xa Inhibitors - adverse effects | Aged | Hemorrhage - chemically induced | Percutaneous Coronary Intervention | Prevention | Complications and side effects | Angiography | Atrial fibrillation | Hemorrhage | Patients | Health aspects | Myocardial infarction | Cerebral infarction | Cardiac arrhythmia | Anticoagulants | Aspirin | Stroke | Angioplasty | Coagulation | Thrombosis | Thrombolysis | Bleeding | Fibrillation | Implants | Vitamin K
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 377, Issue 16, pp. 1513 - 1524
In this trial, dabigatran plus a P2Y 12 inhibitor was compared with warfarin plus a P2Y 12 inhibitor and aspirin after PCI in patients with atrial fibrillation... 
MEDICINE, GENERAL & INTERNAL | PERCUTANEOUS CORONARY INTERVENTION | HEART-DISEASE | MYOCARDIAL-INFARCTION | ORAL ANTICOAGULATION | 2011 ACCF/AHA/SCAI GUIDELINE | AMERICAN-COLLEGE | ASSOCIATION TASK-FORCE | TRIPLE THERAPY | ANTIPLATELET THERAPY | CONSENSUS DOCUMENT | Dabigatran - adverse effects | Ticlopidine - therapeutic use | Humans | Middle Aged | Warfarin - adverse effects | Male | Risk | Dabigatran - therapeutic use | Incidence | Warfarin - therapeutic use | Purinergic P2Y Receptor Antagonists - adverse effects | Drug Therapy, Combination - adverse effects | Adenosine - adverse effects | Adenosine - therapeutic use | Female | Aspirin - therapeutic use | Platelet Aggregation Inhibitors - therapeutic use | Ticagrelor | Purinergic P2Y Receptor Antagonists - therapeutic use | Hemorrhage - epidemiology | Atrial Fibrillation - drug therapy | Atrial Fibrillation - therapy | Anticoagulants - therapeutic use | Anticoagulants - adverse effects | Ticlopidine - analogs & derivatives | Adenosine - analogs & derivatives | Clopidogrel | Aged | Hemorrhage - chemically induced | Percutaneous Coronary Intervention | Warfarin | Atrial fibrillation | Dosage and administration | Research | Thromboembolism | Hemorrhage | Health aspects | Myocardial infarction | Cerebral infarction | Cardiac arrhythmia | Anticoagulants | Aspirin | Stroke | Embolisms | Preventive medicine | Thrombosis | Bleeding | Embolism | Fibrillation | Cardiology | Drug therapy | Drug dosages | Geriatrics
Journal Article
Circulation (New York, N.Y.), ISSN 0009-7322, 12/2010, Volume 122, Issue 24, pp. 2619 - 2633
proton pump inhibitors | antiplatelet drugs | gastrointestinal hemorrhage | platelet aggregation inhibitors | aspirin | thienopyridine | AHA Scientific Statements | CYTOCHROME-P450 | CARDIAC & CARDIOVASCULAR SYSTEMS | MYOCARDIAL-INFARCTION | ACID SUPPRESSION | PERCUTANEOUS CORONARY INTERVENTION | CLOPIDOGREL | LOW-DOSE ASPIRIN | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | DISEASE | PERIPHERAL VASCULAR DISEASE | PRASUGREL | PEPTIC-ULCERS | Piperazines - administration & dosage | Prasugrel Hydrochloride | Purinergic P2Y Receptor Antagonists - administration & dosage | Thiophenes - adverse effects | Cardiovascular Diseases - drug therapy | Humans | Thienopyridines - adverse effects | Thienopyridines - metabolism | Piperazines - metabolism | Thiophenes - metabolism | Thiophenes - administration & dosage | Aspirin - administration & dosage | Purinergic P2Y Receptor Antagonists - metabolism | Histamine H2 Antagonists - administration & dosage | Purinergic P2Y Receptor Antagonists - adverse effects | Drug Interactions | Proton Pump Inhibitors - administration & dosage | Aspirin - adverse effects | Aspirin - metabolism | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Ticlopidine - metabolism | Ticlopidine - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - metabolism | Platelet Aggregation Inhibitors - metabolism | Drug Therapy, Combination | Platelet Aggregation Inhibitors - adverse effects | Proton Pump Inhibitors - adverse effects | Thienopyridines - administration & dosage | Risk Factors | Histamine H2 Antagonists - adverse effects | Piperazines - adverse effects | Ticlopidine - analogs & derivatives | Aryl Hydrocarbon Hydroxylases - metabolism | Gastrointestinal Hemorrhage - chemically induced | Gastrointestinal Hemorrhage - prevention & control | Histamine H2 Antagonists - metabolism | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Cytochrome P-450 CYP2C19 | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Proton Pump Inhibitors - metabolism
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2014, Volume 371, Issue 11, pp. 1016 - 1027
.... Effective antiplatelet therapy combining the inhibition of both thromboxane A 2 –dependent platelet aggregation and P2Y 12 receptors is necessary in patients undergoing percutaneous coronary intervention (PCI... 
MEDICINE, GENERAL & INTERNAL | PERCUTANEOUS CORONARY INTERVENTION | GLYCOPROTEIN IIB/IIIA INHIBITORS | CLOPIDOGREL | MANAGEMENT | INITIATION | PLATELET INHIBITION | DOUBLE-BLIND | IIB-IIIA INHIBITORS | PRASUGREL | PRIMARY ANGIOPLASTY | Myocardial Infarction - mortality | Purinergic P2Y Receptor Antagonists - administration & dosage | Humans | Middle Aged | Male | Purinergic P2Y Receptor Antagonists - adverse effects | Adenosine - adverse effects | Ticlopidine - adverse effects | Ticlopidine - administration & dosage | Female | Drug Therapy, Combination | Myocardial Infarction - diagnosis | Double-Blind Method | Time-to-Treatment | Anticoagulants - therapeutic use | Electrocardiography - drug effects | Adenosine - administration & dosage | Anticoagulants - adverse effects | Ticlopidine - analogs & derivatives | Coronary Angiography | Myocardial Infarction - drug therapy | Myocardial Reperfusion | Adenosine - analogs & derivatives | Aged | Hemorrhage - chemically induced | Emergency Medical Services | Administration | Care and treatment | Hospitals | Research | Management | Heart attack | Risk factors | Myocardial infarction | Heart attacks | Catheterization | Angiography | Clinical trials | Patients | Thrombosis | Thrombolysis | Bleeding | Clinical outcomes | Studies | Reperfusion | Blood platelets | Coronary vessels | Implants | Intubation | Acute coronary syndromes | Drug therapy | Infart de miocardi | Adenosine | Malalties coronàries | Anticoagulants (Medicine) | Anticoagulants (Medicina) | Adenosina | Coronary diseases
Journal Article
The American journal of gastroenterology, ISSN 0002-9270, 12/2010, Volume 105, Issue 12, pp. 2533 - 2549
This expert consensus document was developed by the American College of Cardiology Foundation (ACCF), the American College of Gastroenterology (ACG), and the... 
proton pump inhibitors | aspirin | ACCF Expert Consensus Document antiplatelet drugs | gastrointestinal hemorrhage | thienopyridine | platelet aggregation inhibitors | CYTOCHROME-P450 | MYOCARDIAL-INFARCTION | ACID SUPPRESSION | PERCUTANEOUS CORONARY INTERVENTION | CLOPIDOGREL | LOW-DOSE ASPIRIN | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | DISEASE | PRASUGREL | GASTROENTEROLOGY & HEPATOLOGY | PEPTIC-ULCERS | Piperazines - administration & dosage | Prasugrel Hydrochloride | Purinergic P2Y Receptor Antagonists - administration & dosage | Thiophenes - adverse effects | Cardiovascular Diseases - drug therapy | Humans | Thienopyridines - adverse effects | Thienopyridines - metabolism | Piperazines - metabolism | Thiophenes - metabolism | Thiophenes - administration & dosage | Aspirin - administration & dosage | Purinergic P2Y Receptor Antagonists - metabolism | Histamine H2 Antagonists - administration & dosage | Purinergic P2Y Receptor Antagonists - adverse effects | Drug Interactions | Proton Pump Inhibitors - administration & dosage | Aspirin - adverse effects | Aspirin - metabolism | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Ticlopidine - metabolism | Ticlopidine - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - metabolism | Platelet Aggregation Inhibitors - metabolism | Drug Therapy, Combination | Platelet Aggregation Inhibitors - adverse effects | Proton Pump Inhibitors - adverse effects | Thienopyridines - administration & dosage | Risk Factors | Histamine H2 Antagonists - adverse effects | Piperazines - adverse effects | Ticlopidine - analogs & derivatives | Aryl Hydrocarbon Hydroxylases - metabolism | Gastrointestinal Hemorrhage - chemically induced | Gastrointestinal Hemorrhage - prevention & control | Histamine H2 Antagonists - metabolism | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Cytochrome P-450 CYP2C19 | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Proton Pump Inhibitors - metabolism
Journal Article
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 2014, Volume 64, Issue 10, pp. 1005 - 1014
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2015, Volume 372, Issue 19, pp. 1791 - 1800
... established. We investigated the efficacy and safety of ticagrelor, a P2Y(12) receptor antagonist with established efficacy after an acute coronary syndrome, in this context... 
MEDICINE, GENERAL & INTERNAL | HEART-DISEASE | CLOPIDOGREL | MANAGEMENT | ESC GUIDELINES | AMERICAN-COLLEGE | PREVENTION | ASSOCIATION TASK-FORCE | ACUTE CORONARY SYNDROMES | PRASUGREL | ASPIRIN | Purinergic P2Y Receptor Antagonists - administration & dosage | Double-Blind Method | Drug Administration Schedule | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Risk | Secondary Prevention | Adenosine - administration & dosage | Aspirin - administration & dosage | Purinergic P2Y Receptor Antagonists - adverse effects | Myocardial Infarction - drug therapy | Adenosine - adverse effects | Adenosine - analogs & derivatives | Intracranial Hemorrhages - chemically induced | Platelet Aggregation Inhibitors - administration & dosage | Cardiovascular Diseases - mortality | Female | Aged | Hemorrhage - chemically induced | Drug Therapy, Combination | Platelet Aggregation Inhibitors - adverse effects | Dose-response relationship (Biochemistry) | Treatment outcome | Care and treatment | Safety and security measures | Analysis | Dosage and administration | Ticagrelor | Heart attack | Risk factors | Myocardial infarction | Cerebral infarction | Aspirin | Stroke | Heart attacks | Hemorrhage | Long term | Patients | Thrombolysis | Bleeding | Blood platelets | Antagonist drugs | Cardiovascular diseases | Drug therapy | Life Sciences | Human health and pathology
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2013, Volume 369, Issue 11, pp. 999 - 1010
Journal Article